Antibody-drug conjugates are active in patients with HER2-positive breast cancer brain metastases: where do we go from here?
作者信息
Sammons S, Lin N U
机构信息
Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Harvard Medical School, Boston, USA.
Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Harvard Medical School, Boston, USA.
出版信息
ESMO Open. 2024 May;9(5):102990. doi: 10.1016/j.esmoop.2024.102990. Epub 2024 Apr 24.
Abstract
摘要
相似文献
1
Antibody-drug conjugates are active in patients with HER2-positive breast cancer brain metastases: where do we go from here?抗体药物偶联物在HER2阳性乳腺癌脑转移患者中具有活性：我们从这里何去何从？
ESMO Open. 2024 May;9(5):102990. doi: 10.1016/j.esmoop.2024.102990. Epub 2024 Apr 24.
2
Concurrent antibody-drug conjugates and radiotherapy: a new perspective on radiation necrosis in HER2-positive breast cancer brain metastases from the DESTINY-Breast03 and HER2CLIMB trials.抗体药物偶联物与放疗联合应用：来自DESTINY-Breast03和HER2CLIMB试验的HER2阳性乳腺癌脑转移患者放射性坏死的新视角
ESMO Open. 2024 Jul;9(7):103620. doi: 10.1016/j.esmoop.2024.103620. Epub 2024 Jun 18.
3
The evolving role of trastuzumab emtansine (T-DM1) in HER2-positive breast cancer with brain metastases.曲妥珠单抗-美坦新偶联物（T-DM1）在 HER2 阳性乳腺癌伴脑转移中的不断演变的作用。
Crit Rev Oncol Hematol. 2019 Nov;143:20-26. doi: 10.1016/j.critrevonc.2019.07.010. Epub 2019 Aug 12.
4
ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer.ARX788，一种新型抗 HER2 抗体药物偶联物，在曲妥珠单抗耐药的 HER2 阳性乳腺癌和胃癌的临床前模型中显示出抗肿瘤作用。
Cancer Lett. 2020 Mar 31;473:156-163. doi: 10.1016/j.canlet.2019.12.037. Epub 2020 Jan 2.
5
Trastuzumab deruxtecan in breast cancer.曲妥珠单抗-德鲁替康在乳腺癌中的应用。
Crit Rev Oncol Hematol. 2024 Jun;198:104355. doi: 10.1016/j.critrevonc.2024.104355. Epub 2024 Apr 16.
6
Changing Natural History of HER2-Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies.新型靶向治疗时代下 HER2 阳性乳腺癌脑转移自然史的改变
Clin Breast Cancer. 2018 Feb;18(1):29-37. doi: 10.1016/j.clbc.2017.07.017. Epub 2017 Aug 9.
7
A novel humanized MUC1 antibody-drug conjugate for the treatment of trastuzumab-resistant breast cancer.一种新型人源化 MUC1 抗体药物偶联物，用于治疗曲妥珠单抗耐药的乳腺癌。
Acta Biochim Biophys Sin (Shanghai). 2021 Dec 8;53(12):1625-1639. doi: 10.1093/abbs/gmab141.
8
[New approval: Trastuzumab-deruxtecan for metastatic breast cancer HER2].[新批准：曲妥珠单抗-德曲妥珠单抗用于转移性乳腺癌HER2]
Bull Cancer. 2021 Sep;108(9):783-784. doi: 10.1016/j.bulcan.2021.05.001. Epub 2021 Jun 16.
9
Investigational antibody-drug conjugates in clinical trials for the treatment of breast cancer.用于治疗乳腺癌的临床试验中的研究性抗体药物偶联物。
Expert Opin Investig Drugs. 2021 Aug;30(8):789-795. doi: 10.1080/13543784.2021.1940950. Epub 2021 Jun 21.
10
Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.在 HER2 阳性乳腺癌中实施抗体药物偶联物 (ADC)：现状和未来方向。
Breast Cancer Res. 2021 Aug 11;23(1):84. doi: 10.1186/s13058-021-01459-y.
本文引用的文献
1
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.曲妥珠单抗-德鲁替康与曲妥珠单抗-美坦新在随机 DESTINY-Breast03 试验中用于 HER2 阳性转移性乳腺癌伴脑转移患者的比较。
ESMO Open. 2024 May;9(5):102924. doi: 10.1016/j.esmoop.2024.102924. Epub 2024 Apr 24.
2
Rise of Antibody-Drug Conjugates: The Present and Future.抗体药物偶联物的兴起：现状与未来。
Am Soc Clin Oncol Educ Book. 2023 May;43:e390094. doi: 10.1200/EDBK_390094.
3
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.曲妥珠单抗-德鲁替康对比曲妥珠单抗-美坦新用于治疗 HER2 阳性转移性乳腺癌患者：来自随机、开放标签、III 期 DESTINY-Breast03 研究的更新结果。
Lancet. 2023 Jan 14;401(10371):105-117. doi: 10.1016/S0140-6736(22)02420-5. Epub 2022 Dec 7.
4
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial.图卡替尼对比安慰剂，均联合曲妥珠单抗和卡培他滨，用于治疗先前接受过治疗的 ERBB2（HER2）阳性转移性乳腺癌且伴有脑转移的患者：HER2CLIMB 随机临床试验的更新探索性分析。
JAMA Oncol. 2023 Feb 1;9(2):197-205. doi: 10.1001/jamaoncol.2022.5610.
5
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial.曲妥珠单抗-德鲁替康治疗 HER2 阳性乳腺癌伴脑转移：一项单臂、2 期临床试验。
Nat Med. 2022 Sep;28(9):1840-1847. doi: 10.1038/s41591-022-01935-8. Epub 2022 Aug 8.
6
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial.曲妥珠单抗 deruxtecan 治疗人表皮生长因子受体 2 阳性乳腺癌伴中枢神经系统转移患者：DEBBRAH 试验。
Neuro Oncol. 2023 Jan 5;25(1):157-166. doi: 10.1093/neuonc/noac144.
7
Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumors.抗体药物偶联物的均一性对脑肿瘤的治疗效果有重大影响。
Cell Rep. 2022 May 24;39(8):110839. doi: 10.1016/j.celrep.2022.110839.
8
Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial.NALA 试验中中枢神经系统转移亚组患者接受奈拉替尼联合卡培他滨的疗效。
Oncologist. 2021 Aug;26(8):e1327-e1338. doi: 10.1002/onco.13830. Epub 2021 Jun 7.
9
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.在 HER2CLIMB 试验中，曲妥珠单抗联合卡培他滨治疗既往治疗的 HER2 阳性乳腺癌伴脑转移的颅内疗效和生存。
J Clin Oncol. 2020 Aug 10;38(23):2610-2619. doi: 10.1200/JCO.20.00775. Epub 2020 May 29.
10
TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.TBCRC 022：曲妥珠单抗联合卡培他滨治疗人表皮生长因子受体 2 阳性乳腺癌伴脑转移的 II 期临床试验。
J Clin Oncol. 2019 May 1;37(13):1081-1089. doi: 10.1200/JCO.18.01511. Epub 2019 Mar 12.
Zotero 插件